Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials
Summary
This summary is machine-generated.Gene therapy for gliomas can cause long-term brain inflammation and myelin loss, even after tumor inhibition. Persistent gene expression necessitates careful patient monitoring in future glioblastoma trials.
Area Of Science
- Neuro-oncology
- Gene Therapy
- Immunology
Background
- Adenovirus-mediated gene therapy shows promise for glioma treatment.
- Long-term effects of this therapy on the brain are not well understood.
Purpose Of The Study
- To investigate the long-term consequences of adenovirus-mediated gene therapy for gliomas.
- To assess brain inflammation, demyelination, and transgene expression post-therapy.
Main Methods
- Adenovirus-mediated conditional cytotoxic gene therapy in a syngeneic glioma model.
- Histopathological analysis for inflammatory markers, demyelination, and gene expression at 3 months post-therapy.
Main Results
- Successful inhibition of glioma growth was observed.
- Significant active brain inflammation, including macrophages, microglia, astrocytes, and T lymphocytes, was detected.
- Secondary demyelination and widespread herpes simplex virus 1 thymidine kinase and vector genomes were found throughout the brain.
Conclusions
- Long-term gene therapy for gliomas can lead to persistent brain inflammation and myelin damage.
- Clinical trial designs must consider these adverse effects alongside tumor-killing efficiency.
- Ongoing monitoring for inflammation and transgene expression is crucial for patient safety.
View abstract on PubMed